Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]